Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Status:
Completed
Trial end date:
2016-08-25
Target enrollment:
Participant gender:
Summary
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients
with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard
chemotherapy and biological agents.